Onco Actu du 17 juin 2015

	2.6 Etiologie - Environnement
DDT may quadruple breast cancer risk [Science] The study relies on a unique database of pregnancies in members of the Kaiser Foundation Health Plan in Oakland, California, between 1959 and 1967, when DDT was still used heavily on crops.
The teachers who say their classrooms gave them cancer [BBC News] Teachers must be protected from the "scourge of asbestos" in UK schools, the National Union of Teachers has said. Two former teachers tell how they have been affected.
	3.1 Tabac
Fifteen years after smokers quit, heart failure risk may fall to normal [Reuters] “To date, this is the first study that investigated the role of amount and duration of prior smoking on the health benefits of prolonged cessation for former smokers,” said Dr. Gerasimos Siasos of Brigham and Women's Hospital in Boston, Massachusetts, who was not part of the study.
	4.12 Biopsies liquides
Seeking rare cells [MIT News] In a blood sample taken from a cancer patient, there may be a single circulating tumor cell among hundreds of thousands of other cells. These tumor cells can provide valuable information about how cancer progresses, and could help doctors decide how to treat individual patients, but they are extremely difficult to find.
Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test [Genomic Health] Results Presented at AACR Demonstrate Company's Ability to Monitor Bladder Cancer Using Non-Invasive Urine Test with Accuracy Comparable to Cystoscopy.
	4.9 Dép., diag. & prono. - Sein
Karsten Juhl Jørgensen: Why do five recent reports on breast screening reach conflicting conclusions? [BMJ] Interestingly, the studies that the IARC/WHO and EUROSCREEN Working Group found were most reliable had panel members as authors. Both the selection of panel members, and the public announcement of strong pro-screening messages in a field of substantial scientific controversy without access to the analyses behind them, are a serious threat to the credibility and authority of the WHO and IARC.
	5. Traitements
Radiation experts unite to streamline cancer clinical trials [Cancer Research UK] The new system has been drawn up by leading experts from across the medical physics and clinical radiology communities. It provides a standardised way of assuring that exposure to ionising radiation during clinical trials remains within safe limits, while also cutting down dramatically on duplication of work.
Enhancing the Clinical Trials Search Function on Cancer.gov [National Cancer Institute] These improvements enable patients and health care providers to more easily find accurate and timely information about active and recruiting NCI-supported cancer clinical trials.
	5.12 Immunothérapies
June Is Cancer Immunotherapy Month [CANCER RESEARCH Catalyst] In recognition of June as Cancer Immunotherapy Month, organized by our colleagues at the Cancer Research Institute (CRI), the American Association for Cancer Research (AACR) has compiled the following resources.
	5.2 Pharma
Genticel Receives FDA Clearance of IND Application for U.S. Phase 1 Clinical Trial of GTL001 (ProCervix), Company’s First-in-class HPV Therapeutic Vaccine Candidate [Genticel] The U.S. phase 1 study is designed to evaluate the tolerability and safety of GTL001 as a therapeutic vaccine in 20 women aged 25 to 65 infected with HPV 16 and/or 18. Three investigational sites will be recruiting these patients during the second half of 2015.
Bayer to Present New Data on Copanlisib in Hematological Malignancies [Bayer] Copanlisib is Bayer’s most advanced hematological oncology compound and one of Bayer’s key pipeline assets with a broad clinical development program of Phase II and Phase III studies / Phase III trial CHRONOS-2 open for enrollment, Phase III trial CHRONOS-3 expected to open for enrollment in second half of 2015.
	5.2.2 Pharma - Fusions & Acquisitions
For Pharma, the Hollywood Model of Buying Pipeline Hits is not a Panacea [Wall Street Journal] In fact, the analysis found that few drug makers were able to license one or more blockbuster medicines over that 10-year period, despite a large number of deals.
	5.2.3 Pharma - économie
With IPO in mind, cancer player CytomX steps up with a $70M round [FierceBiotech] There's also a play to be made in reengineered T cell therapies as well, says McCarthy, who hasn't ignored the overnight fame that awaited CAR-T companies like Juno and Kite. Probodies could play a role in enhancing the safety of these therapies.
Shifting to Cancer Immunotherapy, CytomX Bags $70M In Crossover Cash [Xconomy] CytomX’s specialty is a type of antibody it calls a “Probody,” which is supposed to stay inactive in the patient until it gets to the specific area it’s meant to affect. In the case of cancer, that area is known as the tumor microenvironment.
GlaxoSmithKline, Searching for Hit Drugs, Pours $95M into the 'Living Genome' [Forbes] Rather than invest in its own labs which have been downsized and re-organized in many ways, GSK is investing $95 million over the next five years, and potentially that amount and more over the subsequent five years, in a new nonprofit research center in Seattle called the Altius Institute for Biomedical Sciences.
New Juno HQ, Altius debut are signs biotech industry is thriving in Seattle [The Seattle Times] If the industry seems to be rolling in cash, Nelsen put it in perspective when he joked to the groundbreaking crowd, “The cure for cancer may some day be worth as much as a dating app or a taxi service.”
	5.4 Traitements - Economie
Americans say Big Pharma, not insurers, to blame for sky-high drug bills [FiercePharma] As CNBC reports, almost three-quarters of respondents to the Kaiser Health Tracking Poll said their medication costs too much. And about the same number--76%--said it's because pharma companies set prices too high.
How Much?! Global Prescription Drug Sales Forecast to Reach $987B by 2020 [Wall Street Journal] “For the industry to sustain this impressive growth they will have to make compromises around global pricing and market access,” she added. Drug makers will “need to either accept lower prices for products, or persuade payers that the therapeutic benefits outweigh the cost of disease.”
	6. Lutte contre les cancers
State-of-the-art research centre will transform cancer treatment [Cancer Research UK] The flagship building provides more than 6,000m2 for expansion of research activity and has been designed to maximize the sharing of ideas and collaborations between scientists and clinicians.
	6.1 Observation
Breast Cancers Are Rising in Younger And In Older Women: Reasons For Concern [Forbes] The hike in invasive cases cannot simply be explained by screening. Here’s why: the CDC’s NCHS data on mammography use (Fig. 13) reveal that screening’s been flat since 2000.
	6.11 Patients
'Stop Googling your symptoms', teenage cancer victim told before death [The Telegraph] "This has put the spotlight on how the internet age and the availability of information can challenge the way we respond to patients who may be very well informed, but can remain frightened and vulnerable."
	6.3 Associations
Breast cancer gets a newly renamed charity - and new hope [The Telegraph] Breast Cancer Campaign and Breakthrough Breast Cancer yesterday unveiled the name of the new charity, ‘Breast Cancer Now’ and, today, revealed the name of its Patron – H.R.H.The Prince of Wales.
	6.6 Publications
Some things we know about incomplete study reporting and publication bias [The Incidental Economist] I think that’s worth emphasizing: We should be suspicious of all publication oddities and omissions, not just those that are associated with industry. A lot of NIH-sponsored findings—most of them—never see publication too.
	6.9 Controverses
Cancer patient takes BRCA1 gene mutation patent decision to high court [The Guardian] A long-running fight to stop private companies from owning the rights to isolated human gene mutations has reached Australia’s high court, and is the last legal hope for those seeking to stop gene patenting.